{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:54:57Z","timestamp":1790456097554,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Clin. Diabetes Healthc."],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of dapagliflozin plus pioglitazone versus comparators on metabolic control and hepatic steatosis in adults with type 2 diabetes mellitus (T2DM), with or without metabolic dysfunction-associated steatotic liver disease (MASLD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of randomized and observational studies in PubMed, Embase, Cochrane Central, Scopus, Web of Science with a search updated through January 2026, following peer review. Eligible studies enrolled adults with T2DM with or without MASLD, receiving dapagliflozin plus pioglitazone in comparison with standard care or monotherapy, or as pooled-arm exploratory estimates. The primary outcome was glycemic control (HbA1c and fasting and postprandial glucose levels). Secondary outcomes included body weight, insulin resistance indices, related liver outcomes (liver fat content, NAFLD activity score [NAS], and steatohepatitis resolution), liver enzymes, non-invasive fibrosis indices, lipid parameters, and safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen studies (n = 1411) met the inclusion criteria. Dapagliflozin\u2013pioglitazone significantly improved glycemic control, with a reduction in HbA1c (mean difference \u22120.49%; 95% CI \u22120.64 to \u22120.34), and Fasting Blood Glucose (\u221211.96 mg\/dL; 95% CI \u221216.30 to \u22127.62) and Post-Prandial Glucose (\u221221.54 mg\/dL; 95% CI \u221230.84 to \u221212.24). Hepatic outcomes also improved, with reductions in liver fat content (standardized mean difference \u22120.42; 95% CI \u22120.61 to \u22120.22) and NAS (standardized mean difference \u22120.39; 95% CI \u22120.56 to \u22120.22), and higher rates of steatohepatitis resolution (risk ratio 1.48; 95% CI 1.13\u20131.92). Certainty of evidence was moderate for glycemic and steatosis outcomes and low for histological endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dapagliflozin\u2013pioglitazone combination therapy was associated with improvements in glycemic control and non-invasive markers of hepatic steatosis in adults with T2DM, with or without MASLD, while maintaining a favorable safety profile. Certainty of evidence was moderate for metabolic and steatosis outcomes and low for histological endpoints. Given the predominance of surrogate hepatic endpoints and limited biopsy-confirmed data, these findings should be interpreted with appropriate caution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=1117019<\/jats:ext-link>\n                      , identifier CRD420251117019.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcdhc.2026.1733995","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:34:46Z","timestamp":1784525686000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Dapagliflozin &amp; pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study"],"prefix":"10.3389","volume":"7","author":[{"given":"Shashank","family":"Joshi","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Lilavati Hospital and Research Centre","place":["Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambo Samrat","family":"Samajdar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, JMN Medical College and Hospital","place":["Ranaghat, West Bengal, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Gupta","sequence":"additional","affiliation":[{"name":"RHL\u2013Rajasthan Hospital","place":["Jaipur, Rajasthan, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun","family":"Bhartia","sequence":"additional","affiliation":[{"name":"Apollo Hospital","place":["Guwahati, Assam, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailesh","family":"Lodha","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Eternal Hospital","place":["Jaipur, Rajasthan, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supratik","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"SKN Diabetes and Endocrine Centre","place":["Kolkata, West Bengal, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Seshadri","sequence":"additional","affiliation":[{"name":"Chennai Diabetes and Endocrine Clinic, Apollo Hospitals","place":["Chennai, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nagendra","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research","place":["Mysore, Karnataka, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"Unnikrishnan","sequence":"additional","affiliation":[{"name":"Chellaram Diabetes Institute","place":["Pune, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dakshata","family":"Padhye","sequence":"additional","affiliation":[{"name":"Conquer Diabetes Clinic","place":["Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi Nalini","family":"Kopalle","sequence":"additional","affiliation":[{"name":"Fernandez Foundation Unit 1","place":["Hyderabad, Telangana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Kumar","family":"Das","sequence":"additional","affiliation":[{"name":"Mahatma Gandhi Medical College and Research Centre","place":["Pondicherry, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Om","family":"Lakhani","sequence":"additional","affiliation":[{"name":"Zydus Hospital","place":["Ahmedabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jothydev","family":"Kesavadev","sequence":"additional","affiliation":[{"name":"Jothydev\u2019s Diabetes Research Centre","place":["Trivandrum, Kerala, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameya","family":"Joshi","sequence":"additional","affiliation":[{"name":"Bhaktivedanta Hospital & Research Institute","place":["Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sambit","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Kalinga Institute of Medical Sciences","place":["Bhubaneswar, Odisha, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Gadia","sequence":"additional","affiliation":[{"name":"Scientific Services, USV Pvt Ltd","place":["Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamburaj","family":"Anthuvan","sequence":"additional","affiliation":[{"name":"Sales & Marketing and PhD Scholar, USV Private Limited and Pimpri Chinchwad Education Trust (PCET)\u2019s S.B. Patil Institute of Management (Savitribai Phule Pune University)","place":["Mumbai, Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"B1","unstructured":"Diabetes Atlas 2025\n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16455","article-title":"Preventing diabetes complications","volume":"54","author":"Templer","year":"2024","journal-title":"Intern Med J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5551\/jat.65551","article-title":"A comprehensive analysis of diabetic complications and advances in management strategies","volume":"32","author":"Iwasaki","year":"2025","journal-title":"J Atheroscler Thromb"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global prevalence of nonalcoholic fatty liver disease: An updated review meta-analysis comprising a population of 78 million from 38 countries","volume":"55","author":"Amini-Salehi","year":"2024","journal-title":"Arch Med Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: Expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","article-title":"Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Mellemkj\u00e6r","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and Malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2025.103209","article-title":"Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes","volume":"19","author":"Misra","year":"2025","journal-title":"Diabetes Metab Syndr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v23i2.48","article-title":"Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"23","author":"Hu","year":"2023","journal-title":"Afr Health Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.16496","article-title":"Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective","author":"Zargar","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: The need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1420485","article-title":"Synergistically improved cardiovascular outcomes in type 2 diabetes mellitus patients with combined treatment of SGLT-2 inhibitors and pioglitazone","volume":"15","author":"Li","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2337\/dsi23-0012","article-title":"Pharmacological approaches to nonalcoholic fatty liver disease: Current and future therapies","volume":"37","author":"Genua","year":"2024","journal-title":"Diabetes Spectr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13098-026-02086-3","article-title":"Efficacy and safety of fixed-dose dapagliflozin-pioglitazone in Indian adults with type 2 diabetes: Results from the randomized phase 3 PRO-1 trial","volume":"18","author":"Singh","year":"2026","journal-title":"Diabetol Metab Syndr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13546","article-title":"Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study","volume":"21","author":"Abdul-Ghani","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.06.023","article-title":"Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: A multicenter, randomized, double-blind, and placebo-controlled study","volume":"46","author":"Cho","year":"2024","journal-title":"Clin Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12652","article-title":"Revitalization of pioglitazone: The optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor","volume":"18","author":"DeFronzo","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0314","article-title":"Pioglitazone as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with dapagliflozin and metformin: Double-blind, randomized, placebo-controlled trial","volume":"48","author":"Heo","year":"2024","journal-title":"Diabetes Metab J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15526","article-title":"A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin","volume":"26","author":"Lim","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S512872","article-title":"Enhancing diabetes treatment: Comparing pioglitazone\/metformin with dapagliflozin versus basal insulin\/metformin in type 2 diabetes","volume":"19","author":"Lin","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitors, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/30502071241281419","article-title":"Effects of SGLT2 inhibitors and pioglitazone on FIB-4 index in patients with metabolic dysfunction associated steatotic liver disease\u2014A real world retrospective study from India","volume":"1","author":"Seshadri","year":"2024","journal-title":"Int J Clin Metab Diabetes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3797\/scipharm.1407-16","article-title":"Pioglitazone and endothelial dysfunction: Pleiotropic effects and possible therapeutic implications","volume":"82","author":"Radenkovi\u0107","year":"2014","journal-title":"Sci Pharm"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.70066","article-title":"Liver function effects of SGLT2 inhibitors and GLP-1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)","volume":"16","author":"Tsuriya","year":"2025","journal-title":"J Diabetes Investig"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv239","article-title":"Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes","volume":"36","author":"Ferrannini","year":"2015","journal-title":"Eur Heart J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMc1712572","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.50","article-title":"Sodium-glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials","volume":"2","author":"Liao","year":"2018","journal-title":"Endocrinol Diabetes Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16049","article-title":"Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes\u2014A real-world study","volume":"27","author":"Lee","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110685","article-title":"Pioglitazone, SGLT2is and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database","volume":"200","author":"Lo","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15576","article-title":"Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database","volume":"26","author":"Anson","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2025.108998","article-title":"Comparison of efficacy and safety of pioglitazone and SGLT2 inhibitors in treating Asian patients in MASLD associated with type 2 diabetes: A meta-analysis","volume":"39","author":"Liu","year":"2025","journal-title":"J Diabetes Complications"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0282","article-title":"Sodium-glucose cotransporter 2 inhibitor use and risk of liver-related events in patients with type 2 diabetes: A meta-analysis of observational cohort studies","volume":"48","author":"Mantovani","year":"2025","journal-title":"Diabetes Care"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14061960","article-title":"SGLT2 inhibitors and the risk of urogenital infections: A concise review","volume":"14","author":"Confederat","year":"2025","journal-title":"J Clin Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.080486","article-title":"Long-term use of thiazolidinediones and fractures in type 2 diabetes: A meta-analysis","volume":"180","author":"Loke","year":"2009","journal-title":"CMAJ"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: Current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.59556\/japi.73.1250","article-title":"Evaluating pioglitazone for managing type 2 diabetes mellitus in patients with nonalcoholic fatty liver disease","volume":"73","author":"Panikar","year":"2025","journal-title":"J Assoc Physicians India"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"}],"container-title":["Frontiers in Clinical Diabetes and Healthcare"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2026.1733995\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:34:47Z","timestamp":1784525687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2026.1733995\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":50,"alternative-id":["10.3389\/fcdhc.2026.1733995"],"URL":"https:\/\/doi.org\/10.3389\/fcdhc.2026.1733995","relation":{},"ISSN":["2673-6616"],"issn-type":[{"value":"2673-6616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"article-number":"1733995"}}